Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA

  • YanJia Du Meizhou People's Hospital
  • Ya Wen Meizhou People's Hospital
  • JieYu Huang Meizhou People's Hospital
DOI: https://doi.org/10.5937/jomb0-37083
Keywords: Lung cancer, Carcinoembryonic antigen, Cytokeratin 19 fragment, Squamous cell carcinoma antigen, Ultrasound-guided transbronchial needle aspiration, Joint diagnosis, Diagnostic value, Pathological type

Abstract


Objective: To explore the variation of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and squamous cell carcinoma (SCC) antigen in patients with lung cancer (LC) and their diagnostic value with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

Methods: Selection of 150 patients with suspected lung malignant lesions as the research objects was to analyze the diagnostic value of serum tumor marker test and EBUS-TBNA joint detection for LC.

Results: The AUC of joint examination to diagnose LC and identify pathological types of LC was elevated vs. alone detection of each index.

Conclusions: Serum CYFRA21-1, SCC and CEA conjugating with EBUS-TBNA are provided with diagnostic value for LC and identified value for pathological types of LC.

References

[1] Dequan Tian, Ting Xu, Yan Zhang, et al. The serum tumor markers in patients of advanced lung cancer with first-line chemotherapy efficacy assessment and survival prediction [J]. Chinese Journal of Laboratory Medicine, 2017, 40(9):693-699.
[2]Wang S, Ma P, Ma G, et al. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis[J]. Eur J Cancer, 2020, 124(1):1-14.
[3]Figueiredo VR, Cardoso PFG, Jacomelli M, et al. EBUS-TBNA versus surgical mediastinoscopy for mediastinal lymph node staging in potentially operable non-small cell lung cancer: a systematic review and meta-analysis[J]. J Bras Pneumol, 2020, 46(6):e20190221.
[4]Lainez S, Tissot C, Cottier M, et al. EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer[J]. Respiration, 2017, 94(6):518-521.
[5]Ji M, Zhang LJ. Expression levels of SCCA and CYFRA 21-1 in serum of patients with laryngeal squamous cell carcinoma and their correlation with tumorigenesis and progression[J]. Clin Transl Oncol, 2021, 23(2):289-295.
[6] Chinese Medical Association, Oncology Branch of Chinese Medical Association, Journal of Chinese Medical Association. Clinical diagnosis and treatment guidelines for lung cancerof Chinese Medical Association (Edition 2018) [J]. Chinese Journal of Oncology, 2018, 40(12):935-964.
[7]. Tumour marker committee of Chinese anti-cancer association. Clinical application of serum markers for lung cancer in Chinese population and establishment of standardized procedures for reference interval [J]. Chinese Journal of Clinical Oncology, 2021, 48(X):1-6.
[8]Chouaid C, Salaün M, Gounant V, et al. Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small–cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB)[J]. PLoS One, 2019, 14(1):e0208992.
[9]Cicek T, Ozturk A, Yılmaz A, et al. Adequacy of Ebus-Tbna Specimen For Mutation Analysis of Lung Cancer[J]. Clin Respir J, 2019, 13(2):92-97.
[10]Kotowicz B, Fuksiewicz M, Jonska-Gmyrek J, et al. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease[J]. Tumour Biol, 2016, 37(1):1271-1278.
[11]Yang Y, Huang X, Zhou L, et al. Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma[J]. BMC Cancer, 2019, 19(1):526-529.
[12]Zhao W, Liu Y, Kong F, et al. Correlations of pathological stage and prognosis of NSCLC patients with changes in serum CEA and CYFRA21-1 and CT characteristics[J]. Panminerva Med, 2020, 62(1):67-69.
[13]Zhu K, Chen L, He C, et al. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers[J]. Dis Markers, 2020, 7(1):1-6.
[14] Nan Zhang, Tiejun Li, Kunpeng Li, et al. Expression and prognostic value of serum tumour markers and chemokine proteins in lung cancer [J]. Chongqing Medicine, 2017, 46(25):3484-3485.
[15]Qu T, Zhang J, Xu N, et al. Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer.[J]. Oncol Lett, 2019, 17(5):4293-4298.
[16] Hui Zhang. The value of single and combined detection of four serum tumor markers in the diagnosis of lung cancer [J]. Chinese Journal of Cancer Prevention and Treatment, 2018, 25(S2): 50-51.
[17]Zhang L, Liu D, Li L, et al. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients[J]. Bmc Cancer, 2017, 17(1):96-100.
[18]Jia K, Li W, Wang F, et al. Novel circulating peptide biomarkers for esophageal squamous cell carcinoma revealed by a magnetic bead-based MALDI-TOFMS assay[J]. Oncotarget, 2016, 7(17):23569-23580.
[19]Muley T, Rolny V, He Y, et al. The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)[J]. Lung Cancer, 2018, 120(6):46-53.
[20]Dal Bello MG, Filiberti RA, Alama A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients[J]. J Transl Med, 2019, 17(1):74-74.
[21] Qianqian Chen, Jia Song, Shuyan Sun. Combined detection of five tumor markers in the diagnosis of lung cancer [J]. Chinese Journal of Gerontology, 2018, 38(7):1597-1598.
[22]Dong Z, Li H, Jiang H, et al. Evaluation of cytology in lung cancer diagnosis based on EBUS-TBNA[J]. J Cytol, 2017, 34(2):73-77.
[23]Singh R, Lal A. EBUS-TBNA for the diagnosis of lung parenchymal lesions[J]. Lung Cancer, 2019, 63(1):45-49.
[24]Righi L, Franzi F, Montarolo F, et al. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing[J]. J Thorac Dis, 2017, 9(5):S395-S404.
[25] Xiaobin Guo, Xiao Li, Keqing Feng. Changes of SCC-associated antigen, carcinoembryonic antigen and CYFRA21-1 in peripheral blood of elderly patients with early non-small cell lung cancer [J]. Chinese Journal of Gerontology, 2017, 37(4):920-921.
Published
2023/11/25
Issue
Ahead of print
Section
Original paper

Copyright (c) 2023 YanJia Du, Ya Wen, JieYu Huang

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.